Omar Eton - Hartford Hospital | 人才画像

基本信息

Career Trajectory

Bio

Expertise includes: Preclinical to clinical transitions in Oncology; Phase 1,2,3,... oncology drug development from blank concept page to IRB protocol approval and successful trial execution and final published manuscript; Melanoma; Tyrosine kinase inhibitors; Tumor immunology; Endocrine tumors; and GI tumors. Interests include nanocarriers and cutting edge discovery agents heading to the clinic.

Research Interests

Papers共 69 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Supplementary Figures 1 from Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study

James W. Smithy,Hannah L. Kalvin,Fiona D. Ehrich,Ronak Shah,Matthew Adamow, Vladislav Raber,Collen A. Maher, Jenna Kleman, Deborah A.G. McIntyre,Alexander N. Shoushtari,Allison Betof Warner,Margaret K. Callahan,Parisa Momtaz,Omar Eton,Suresh Nair,Jedd D. Wolchok,Paul B. Chapman,Michael F. Berger,Katherine S. Panageas,Michael A. Postow

crossref（2024）

Cited0Views0Bibtex

Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study

James W. Smithy,Hannah L. Kalvin,Fiona D. Ehrich,Ronak Shah,Matthew Adamow, Vladislav Raber,Collen A. Maher, Jenna Kleman, Deborah A. G. Mcintyre,Alexander N. Shoushtari,Allison Betof Warner,Margaret K. Callahan,Parisa Momtaz,Omar Eton,Suresh Nair,Jedd D. Wolchok,Paul B. Chapman,Michael F. Berger,Katherine S. Panageas,Michael A. Postow

Clinical Cancer Researchpp.OF1-OF9, (2024)

Cited0Views0WOSBibtex

Interplay of Immunosuppression and Immunotherapy among Patients with Cancer and COVID-19

Ziad Bakouny,Chris Labaki,Punita Grover,Joy Awosika,Shuchi Gulati,Chih-Yuan Hsu,Saif Alimohamed,Babar Bashir,Stephanie Berg,Mehmet A. Bilen,Daniel Bowles,Cecilia Castellano,Aakash Desai,Arielle Elkrief,Omar E. Eton,Leslie A. Fecher,Daniel Flora,Matthew D. Galsky,Margaret E. Gatti-Mays, Alicia Gesenhues,Michael J. Glover,Dharmesh Gopalakrishnan,Shilpa Gupta,Thorvardur R. Halfdanarson,Brandon Hayes-Lattin,Mohamed Hendawi,Emily Hsu,Clara Hwang,Roman Jandarov,Chinmay Jani,Douglas B. Johnson,Monika Joshi,Hina Khan,Shaheer A. Khan,Natalie Knox,Vadim S. Koshkin,Amit A. Kulkarni,Daniel H. Kwon, Sara Matar,Rana R. McKay,Sanjay Mishra,Feras A. Moria,Amanda Nizam,Nora L. Nock,Taylor K. Nonato,Justin Panasci,Lauren Pomerantz,Andrew J. Portuguese,Destie Provenzano,Matthew Puc,Yuan J. Rao,Terence D. Rhodes,Gregory J. Riely,Jacob J. Ripp,Andrea Rivera,Erika Ruiz-Garcia,Andrew L. Schmidt,Adam J. Schoenfeld,Gary K. Schwartz,Sumit A. Shah,Justin Shaya,Suki Subbiah,Lisa M. Tachiki,Matthew D. Tucker,Melissa Valdez-Reyes,Lisa B. Weissmann,Michael T. Wotman,Elizabeth M. Wulff-Burchfield,Zhuoer Xie, Yuanchu James Yang,Michael A. Thompson,Dimpy P. Shah,Jeremy L. Warner,Yu Shyr,Toni K. Choueiri,Trisha M. Wise-Draper

JAMA ONCOLOGY（2023）

Cited33Views0WOSBibtex

Final Clinical Results and First Translational Correlates of a Phase 2 Trial of Adaptively Dosed Nivolumab and Ipilimumab Based on Early Radiographic Assessment in Advanced Melanoma (ADAPT-IT)

James William Smithy,Hannah L. Kalvin, Vladislav Raber,Colleen Anne Maher, Jenna Kleman,Debra A. G. McIntyre,Alexander Noor Shoushtari,Allison Betof Warner,Margaret K. Callahan,Parisa Momtaz,Omar Eton,Suresh Nair,Jedd D. Wolchok,Paul B. Chapman,Katherine Panageas,Michael A. Postow

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023)

Cited3Views0Bibtex

Combining Panitumumab with Anti-PD-1 Antibody in Cutaneous Squamous Cell Carcinoma of the Head and Neck after Inadequate Response to Anti-PD-1 Antibody Alone

Emily Hsu,Omar Eton,Akshay Patel,Richard Cartun,Jonathan S. Earle,Laila O. Mnayer,Jennifer Kotowitz,Peter P. Yu

JOURNAL OF DRUGS IN DERMATOLOGY（2021）

Cited2Views0WOSBibtex

Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (the ADAPT-IT Study)

Michael A. Postow,Debra A. Goldman,Alexander N. Shoushtari,Allison Betof Warner,Margaret K. Callahan,Parisa Momtaz,James W. Smithy,Ellesa Naito,Marina K. Cugliari, Vladislav Raber,Omar Eton,Suresh G. Nair,Katherine S. Panageas,Jedd D. Wolchok,Paul B. Chapman

Journal of Clinical Oncology（2021）

Cited35Views0WOSBibtex

A Phase II Study to Evaluate the Need for > Two Doses of Nivolumab + Ipilimumab Combination (combo) Immunotherapy

Michael A. Postow,Debra A. Goldman,Alexander Noor Shoushtari,Allison Betof Warner,Margaret K. Callahan,Parisa Momtaz,Ellesa Naito,Omar Eton,Suresh Nair,Jedd D. Wolchok,Katherine Panageas,Paul B. Chapman

JOURNAL OF CLINICAL ONCOLOGY（2020）

Cited23Views0Bibtex

467 Anti-EGFR Antibody Added to Ongoing Anti-Pd-1 Antibody Treatment for Metastatic Cutaneous Squamous Cell Carcinoma of the Face: Two Case Reports

Omar Eton,Emily Hsu,Akshay Patel,Richard Cartun,Jonathan Earle,Laila Mnayer, Peter Yu,Jennifer Kotowitz

Regular and Young Investigator Award Abstracts（2020）

Cited3Views0Bibtex

Challenges in Assessing the Clinical Utility and Economic Value of Immune Checkpoint Inhibitor Therapies of Cancer

Yu Peter Paul,Eton Omar,Garrison Louis P.

Journal for ImmunoTherapy of Cancer（2019）

Cited10Views0WOSBibtex

Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAFV600E Mutated Papillary Thyroid Cancer: Two Case Reports

Paul S. White,Anita Pudusseri,Stephanie L. Lee,Omar Eton

Thyroid（2017）

Cited16Views0WOSBibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn